EB-0150

• Description :

  EB-0150 is a potent inhibitor of ER α-glucosidases (α-Glu) Iand II with IC50s of 0.73 and 0.0337 μM, respectively. EB-0150 is a N-substituted derivative of valiolamine with broad-spectrum antiviral. EB-0150 has the potential for the reseach of broad-spectrum agent against the existing and emerging viruses[1]. EB-0150 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

• UNSPSC :

  12352005

• Target :

  Glycosidase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Infection

• Assay Protocol :

  https://www.medchemexpress.com/eb-0150.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O[C@@H]1[C@](O)(C[C@@H]([C@@H]([C@H]1O)O)NCCCCCCNC2=C(C=C(C=C2)N=[N+]=[N-])[N+]([O-])=O)CO

• Molecular Formula :

  C19H30N6O7

• Molecular Weight :

  454.48

• References & Citations :

  [1]Karade SS, et al. N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. J Med Chem. 2021;64 (24) :18010-18024.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2832824-40-3]